Patents by Inventor Lars Fogh Iversen
Lars Fogh Iversen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364248Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: December 19, 2022Publication date: November 16, 2023Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Publication number: 20230212245Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: December 19, 2022Publication date: July 6, 2023Inventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20210198331Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: March 8, 2021Publication date: July 1, 2021Inventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20200079829Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 23, 2018Publication date: March 12, 2020Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 10398782Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: May 23, 2018Date of Patent: September 3, 2019Assignee: Novo Nordisk A/SInventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Publication number: 20190248852Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. 5 The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 24, 2017Publication date: August 15, 2019Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20180339057Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 23, 2018Publication date: November 29, 2018Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 8530217Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: GrantFiled: December 16, 2009Date of Patent: September 10, 2013Assignee: Novo Nordisk A/SInventors: Inga Sig Nielsen Nørby, Lars Fogh Iversen
-
Publication number: 20100197573Abstract: A method for PEGylating growth hormone, said method comprising reacting growth hormone with an amine comprising nucleophile which further comprises a first functional group in the presence og TGase to form a transaminated growth hormone, followed by a reaction of said transaminated growth hormone with a PEG which has been functionalised with a second functional group, wherein said first and second functional groups are selected so that they react to form a covalent bond.Type: ApplicationFiled: June 15, 2006Publication date: August 5, 2010Applicant: Novo Nordisk Health Care AGInventors: Florencio Zaragoza Dorwald, Niels Langeland Johansen, Lars Fogh Iversen
-
Publication number: 20100099142Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: ApplicationFiled: December 16, 2009Publication date: April 22, 2010Applicant: Novo Nordisk A/SInventors: Inga Sig Nielsen Nørby, Lars Fogh Iversen
-
Patent number: 7662935Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: GrantFiled: May 26, 2009Date of Patent: February 16, 2010Assignee: Novo Nordisk A/SInventors: Inga Sig Nielsen Nørby, Lars Fogh Iversen
-
Publication number: 20090269843Abstract: Fusion proteins comprising a first protein fused to hemopexin are provided, said fusion proteins exhibit an increased circulation time.Type: ApplicationFiled: August 16, 2005Publication date: October 29, 2009Applicant: Novo Nordisk A/SInventors: Niels Blume, Jing Su, Ju Han, Lars Fogh Iversen
-
Publication number: 20090253900Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: ApplicationFiled: May 26, 2009Publication date: October 8, 2009Applicant: Novo Nordisk A/SInventors: Inga Sig Nielsen Norby, Lars Fogh Iversen
-
Publication number: 20090042272Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: ApplicationFiled: July 22, 2008Publication date: February 12, 2009Applicant: Novo Nordisk A/SInventors: Inga Sig Nielsen Norby, Lars Fogh Iversen
-
Publication number: 20080305986Abstract: Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides.Type: ApplicationFiled: August 16, 2005Publication date: December 11, 2008Inventors: Killian Waldemar Conde Fieboes, Birgitte Urs, Lars Fogh Iversen
-
Publication number: 20080182783Abstract: Compounds of formula (I) wherein GH represent a radical derived from a growth hormone compound by removal of one hydrogen atom from the N-terminal amino group; X represents oxygen or two hydrogen atoms; Z represents a bond, alkylene, arylene, heteroarylene, —CH2—O—(CH2)1-10—, —CH2—O—(C6H4)—, or combinations thereof; and Y represents a radical selected from are provided together with methods for making said compounds. The compounds are useful in therapy.Type: ApplicationFiled: October 18, 2005Publication date: July 31, 2008Applicant: Novo Nordisk A/SInventors: Florencio Zaragoza Dörwald, Lars Fogh Iversen, Nils Langeland Johansen
-
Patent number: 7115624Abstract: The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTP?, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.Type: GrantFiled: September 11, 2000Date of Patent: October 3, 2006Assignee: Novo Nordisk A/SInventors: Henrik Sune Andersen, Thomas Kruse Hansen, Lars Fogh Iversen, Jesper Lau, Niels Peter Hundahl Møller, Ole Hvilsted Olsen, Frank Urban Axe, Yu Ge, Daniel Dale Holsworth, Todd Kevin Jones, Luke Milburn Judge, Wiliam Charles Ripka, Barry Zvi Shapira, Roy Teruyuki Uyeda
-
Patent number: 6951878Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: May 28, 2002Date of Patent: October 4, 2005Assignee: Novo Nordisk A/SInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Publication number: 20030069267Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.Type: ApplicationFiled: May 28, 2002Publication date: April 10, 2003Inventors: Niels Peter Hundahl Moller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6410586Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: March 16, 2001Date of Patent: June 25, 2002Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda